Efficacy and Safety of Pemetrexed and Gefitinib in the Treatment of Non-Small-Cell Lung Cancer: A Meta-Analysis

Table 1

Primary characteristics of the eligible studies in more detail.

Author	Year	Country	Treatment	No. of patients	Gender (male/female)	Median age	Median follow-up time	Outcomes
Hong J	2010	Korea	C: pemetrexed	20	17/3	62	12.1 months	ORR, DCR, PFS, OS, AE
			T: gefitinib	20	9/11	61
Sun JM	2012	Korea	C: pemetrexed	67	10/57	64	15.9 months	ORR, PFS, OS, AE
			T: gefitinib	68	10/58	58
Dai HY	2013	China	C: pemetrexed	23	14/9	61	NR	ORR, DCR, PFS, AE
			T: gefitinib	23	15/8	62
Zhou Q	2014	China	C: pemetrexed	76	47/29	55.9	10.6 months	ORR, DCR, PFS, OS, AE
			T: gefitinib	81	54/27	57.5
Kim YS	2016	Korea	C: pemetrexed	47	33/14	64	60.6 months	ORR, DCR, PFS, OS, AE
			T: gefitinib	48	35/13	67
Xu YH	2015	China	C: pemetrexed	94	NR	NR	NR	ORR, DCR, AE
			T: gefitinib	94	NR	NR
Lin L	2016	China	C: pemetrexed	48	36/12	57	25 months	ORR, DCR, PFS, OS, AE
			T: gefitinib	53	29/24	59
Liu XM	2015	China	C: pemetrexed	22	13/9	61.3	NR	ORR, DCR, PFS, AE
			T: gefitinib	20	13/7	62.3
Song TT	2015	China	C: pemetrexed	60	36/24	54.9	NR	ORR, DCR, AE
			T: gefitinib	60	38/22	55.7
Wang MQ	2012	China	C: pemetrexed	38	25/13	63.3	NR	ORR, DCR, AE
			T: gefitinib	37	23/14	64.2
Zhang DG	2016	China	C: pemetrexed	55	30/25	65	NR	ORR, DCR, AE
			T: gefitinib	50	17/33	67
Zhang J	2012	China	C: pemetrexed	40	26/14	NR	6 months	ORR, DCR, AE
			T: gefitinib	40	19/21	NR
Zhang YH	2009	China	C: pemetrexed	32	13/15	56	NR	ORR, DCR, AE
			T: gefitinib	35	12/23	58
Zhao LH	2013	China	C: pemetrexed	41	NR	NR	NR	ORR, DCR, AE
			T: gefitinib	42	NR	NR

NR: no report; T: treatment group; C: control group; ORR: overall response rate; DCR: disease control rate; PFS: progression-free survival; OS: overall survival; AE: adverse event.